FDA Approved: ELREXFIO — Supplemental Application (U.S. Pharmaceuticals)

View source ↗

Summary

FDA approved a supplemental application for ELREXFIO (elranatamab-BCMM) from U.S. Pharmaceuticals, resulting in an update to its labeling/indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ELREXFIO (ELRANATAMAB-BCMM)

Snippet

SUPPL AP for ELREXFIO (ELRANATAMAB-BCMM)